Cristina Hickman: Key Insights from EBART 2026 in Reproductive Medicine
Cristina Hickman, Founder and Consultant Clinical Embryologist at Avenues, shared a post on LinkedIn:
“I would like to thank Amelia Rodriguez-Aranda, Marcio Fernandes, and the entire Eugin Group team for a fantastic EBART2026 conference, and for inviting me to share our experience on managing Dropout
Having attended many conferences over the years, this one truly stood out, with an exceptional line up of speakers and cutting edge discussions in reproductive care
A few highlights that fit the linkedin post character count:
- Christos Venetis highlighted the need to look beyond strict reliance on RCTs and to embrace real world evidence where appropriate. He acknowledged limitations in the Illingworth et al 2024 iDAScore study and suggested RWE was better suited for AI assessment than RCTs
On reflection from his talk, it raises an important question: how many patients may have missed the benefits of AI since this RCT was published because of how fertility professionals and regulators incorrectly interpret evidence based medicine? - Tony Gordon presented clear Real world evidence favoring PGT-A
- Samuel Ojosnegros Martos shared fascinating work using hyperspectral technology to better understand blastocyst implantation
- Pietro Santulli and Mats Hellstrom explored advanced approaches to severe adenomyosis and uterine bioengineering
- Nuno Costa Borges discussed mitochondrial donation and the potential of immature GV oocytes for patients over 40 to reduce age related aneuploidy
- Santiago Munne presented exciting progress in automation and vitrification from Overture Life
- Diego Marin and Jonathan Anomaly from Herasight explored the ethical and legal landscape of emerging genetic technologies such as PGT-P, highlighting both their potential and the importance of robust, evidence based application and regulation. The law in countries such as the UK needs to catch up with the technology to better assist patients.
- Willem Ombelet reminded us, through the inspiring Walking Egg project, stripping IVF technologies and literally returning IVF back to the test tube, that accessibility must remain central to global IVF care
In contrast, I shared the Avenues experience: technology is essential to scale access fairly and maximising the chances of having a healthy baby to everyone who wishes to become a parent. By aligning success metrics with patient centred goals and focusing on the full journey rather than individual cycles, we can reduce time to baby, cost to baby, and convenience to baby, while improving experience without sacrificing outcome. This is how we make IVF more accessible to patients globally
Inspired by Louise Brown reflections on the care her parents received from Purdy, Steptoe and Bob Edwards, we are reminded that alongside innovation, compassionate, personalised care must remain at the heart of everything we do. This is key to reducing unnecessary dropout and easing the burden many patients still face today, unnecessarily
Looking forward to continuing these conversations at the AIFertility World conference in Cascais.”

Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Aug 12, 2026, 16:59Aumatma Simmons: Commonly Overlooked Hormone Imbalances Hidden Within “Normal” Range
-
Aug 12, 2026, 16:51Svitlana Yashchenok: AI in IVF – Real Benefit or Marketing Hype?
-
Aug 12, 2026, 16:27Sean Lauber: Rescue In Vitro Maturation – A Technique to Culture Immature Eggs in the Lab
-
Aug 12, 2026, 16:18Ahmed Elhlily: Ovine and Bovine IVF, From Oocytes to Blastocysts
-
Aug 12, 2026, 16:05Akansha Negi: ACE 2026 Advancing in Clinical Embryology
-
Aug 12, 2026, 16:01PCOS Is Breaking the Scaffolding Around Your Eggs – Fertility Plus
-
Aug 12, 2026, 15:46A Low Ovarian Reserve Is Not the Final Answer – Fertility Plus
-
Aug 12, 2026, 15:39PCOS Is More Than the Ovaries: What Patients Need to Know – Montgomery Fertility Center
-
Aug 12, 2026, 15:26Surjeet Singh։ And Just Like That, ACE 2026 Comes to an End
